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Abstract
Similar to all antiretroviral drugs, failure of raltegravir-
based treatment regimens to fully supress HIV replica-
tion almost invariably results in emergence of HIV re-
sistance to this new drug. HIV resistance to raltegravir
is the consequence of mutations located close to the
integrase active site, which can be divided into three
main evolutionary pathways: the N155H, the
Q148R/H/K and the Y143R/C pathways. Each of
these primary mutations can be accompanied by a vari-
ety of secondary mutations that both increase resis-
tance and compensate for the variable loss of viral
replicative capacity that is often associated with prima-
ry resistance mutations. One unique property of HIV
resistance to raltegravir is that each of these different
resistance pathways are mutually exclusive and appear
to evolve separately on distinct viral genomes. Resis-
tance is frequently initiated by viruses carrying muta-
tions of the N155H pathway, followed by emergence
and further dominance of viral genomes carrying mu-
tations of the Q148R/H/K or of the Y143R/C path-
ways, which express higher levels of resistance. Even
if some natural integrase polymorphisms can be part
of this evolution process, these polymorphisms do not
affect HIV susceptibility in the absence of primary
mutations. Therefore, all HIV-1 subtypes and groups,
together with HIV-2, are naturally susceptible to ralte-
gravir. Finally, because interaction of integrase strand
transfer inhibitors with the HIV integrase active site is
comparable from one compound to another, ralte-
gravir-resistant viruses express significant cross resis-
tance to most other compounds of this new class of
antiretroviral drugs.
BASIC PRINCIPLES OF HIV DRUG RESISTANCE
Viral resistance is an almost unavoidable consequence
of the failure of antiretroviral drugs to fully suppress
active HIV replication in treated patients. Two princi-
pal mechanisms explain this phenomenon. First, the
large majority of HIV-producing cells in vivo are highly
activated CD4 T-cells with a remarkably short half-life
[7, 24, 41]. In spite of the short lifespan of these in-
fected cells, the amounts of plasma virus, hence the to-
tal number of infected cells in the body, is usually sta-
ble over time in the absence of treatment. This implies
that there exists a steady state between the rapid clear-
ance of infected cells and the infection of new target
cells by the virus. In consequence, the continuous re-
generation of the pool of infected cells requires that
infectious cycles by the virus be constantly reinitiated.
Second, because of the intrinsically error-prone nature
of reverse transcription of RNA into DNA [43, 46],
each HIV infectious cycle introduces at least one ran-
dom error per viral genome. As persistent HIV infec-
tion requires that multiple cycles of virus replication
be constantly repeated, the population of viruses
found in a single infected individual is highly diverse
and constantly fluctuating over time [6, 36]. In this
context, when the pharmacological pressure exerted by
antiretroviral drugs is unable to fully suppress ongoing
cycles of HIV replication, emergence of viral variants
carrying mutations that reduce HIV susceptibility to
these drugs is almost inevitable.
Resistance is the consequence of mutations that
modify the interaction between antiretroviral drugs and
their viral target. Resistance mutations have been iden-
tified in all viral proteins targeted by antiretroviral
drugs such as RT, protease and the envelope glycopro-
tein. Even when the drug does not directly target
the virus but is directed against a cellular protein that is
required for viral replication (the CCR5 or CXCR4
receptors, for example), mutations in the viral protein
that interacts with the cellular target have been found
to emerge under appropriate conditions [55]. In some
instances, single mutations able to express high-level
resistance : this is the case of reverse transcriptase
mutations M184V, which mediates HIV resistance to
3TC and FTC [3], or of several mutations mediating
resistance to non-nucleoside RT inhibitors (NNRTI)
[2, 45]. These drugs are described as having a low
genetic barrier to resistance. For other drugs, high-level
resistance requires that multiple mutations accumulate
over time, with no single mutation able to promote
significant resistance : these drugs are said to have a
high genetic barrier to resistance [8, 12, 27, 37, 54].
The best examples of such drugs are protease in-
hibitors, to which individual changes in the HIV
protease express only minor changes in susceptibility
and for which development of clinically relevant
resistance levels requires gradual accumulation of
multiple different mutations [8, 27, 37]. The historical
efficacy of highly active antiretroviral therapy
(HAART) in HIV-infected individuals is based both
on its antiviral potency, which most often leads to
complete suppression of active viral replication, and
on its ability to raise a high genetic barrier to viral re-
sistance.
In this context, raltegravir (RAL), the first integrase
strand transfer inhibitor (INSTI) that has been ap-
proved for clinical use, does not fundamentally differ
from other antiretroviral drugs. Virological sudies con-
ducted in patients from clinical trials evaluating RAL
efficacy in vivo have found that resistance to RAL can
emerge rapidly following treatment failure, identified
IN mutations able to mediate high-level resistance to
RAL, and revealed that the genetic barrier of resis-
tance to RAL is relatively low.
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EMERGENCE OF RAL RESISTANCE IN TREATED
PATIENTS
The first observations of HIV resistance to RAL in
vivo essentially came from the BENCHMRK-I and
BENCHMRK-II clinical trials [51]. In these large
phase 2 studies, patients having failed several previous
HAART regimens and infected by viruses expressing
resistance to multiple antiretroviral drugs were pro-
posed a combination of RAL with an « optimized »
background of other drugs, which, based on RT and
PR genotype, were believed to retain significant antivi-
ral activity against the patient’s virus. In a large propor-
tion of these patients (>60%), the RAL-based regimen
was able to stably reduce plasma viremia to unde-
tectable levels, even in instances where the background
regimen was not predicted to be fully active. Not sur-
prisingly, however, in patients with viruses expressing
lower susceptibility to the background regimen, full
suppression of viral replication was more difficult to
reach and viral variants expressing resistance to RAL
were found [9]. The most frequently observed muta-
tions were substitutions N155H, Q148R/H/K and
Y143R/C (Fig. 1). The same mutations were also seen
in a small-scale study by Malet et al. [33], of patients
exhibiting early failure of salvage therapy with a
regimen that included RAL. In these and further stud-
ies [50], some of the viral genomes emerging under
RAL pressure were found to have selected other
mutations that were not present before RAL treatment,
such as mutations L74M, E92Q, T97A, E138A/K,
G140S/A, G163R or V151I (Table 1). Of note,
however, several studies reported that at least during
the first weeks of RAL failure, a significant proportion
of patients harbored viral sequences that did not ex-
hibit any change in their baseline IN sequences [9, 29].
The mechanisms explaining this lack of resistance mu-
tations, and particularly the pharmacological parame-
ters of RAL pressure, were not assessed in these in-
stances.
Overall, it became soon clear that resistance to RAL
can proceed along three principal mutational pathways,
each characterized by the presence of either of the
three major mutations N155H, Q148R/H/K or
Y143R/C [9]. The N155H pathway is frequently asso-
ciated with secondary mutations L74M, E92Q, T97A,
G136R or V151I. The Q148R/H/K pathway is usually
associated with secondary mutations E138A/K or
G140A/S. The third pathway, involving primary muta-
tions Y143C or Y143R, also frequently includes sec-
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Table 1. Amino-acid substitutions observed in viruses escaping RAL treatment (from Sichtig et al., J Antimicrob Ther 2009).
Primary (pathway-specific) mutations N155H, Q148R/H/K, Y143R/C
Secondary mutations L74M, E92Q, T97A, Y143H, V151I, G163R,
E138A/K, G140S/A
Occasional mutations/polymorphisms H51Y, T66I, V72I, L74A/I, S119R/G/P/T,
T112I, F121Y, T125A/K, A128T, Q146K,
S147G, S153Y/A, M154I, K156N, E157Q,
K160D, V165I, V201I, I203M, T206S,
S230R/N, V249I, R263K, C280Y
Fig. 1. Resistance genotypes in pa-
tients failing RAL-based salvage thera-
py in the BENCHMRK study (from
Cooper et al., N Engl J Med 2008).
The bars indicate the proportion of
viruses carrying the indicated muta-
tions within the population of patients
exhibiting virological failure of ralte-
gravir-based therapy.
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ondary mutations such as L74A/I, E92Q, T97A,
I203M and/or S230R.
The aminoacid residues involved in primary resis-
tance to RAL are highly conserved among all HIV sub-
types [5] and are located close to the catalytic site of
the enzyme. Interestingly, minimal overlap exists be-
tween the mutational pathways described as emerging
during RAL failure and the IN mutations observed fol-
lowing in vitro selection for resistance to earlier gener-
ations of INSTI compounds. Indeed, while naphtyri-
dine carboxylate derivatives were found to select for
combinations of substitutions V72I, F121Y, T125K
and V151I [22], diketo acid derivatives essentially led to
emergence of mutation T66I in association with
S153Y or M154I, or of substitution N155S [16, 23].
With these earlier compounds, the selected mutants ap-
peared to express only low levels of resistance at the
expense of marked losses in viral replicative capacity,
which was consistent with the close proximity of some
of the mutations with the key catalytic aminoacids of
the integrase enzyme at positions D64, D116 and
E152. It was therefore somewhat anticipated that mu-
tations emerging under RAL pressure would also ex-
press limited resistance and significantly affect viral fit-
ness, but this turned out not to be the case.
THE UNIQUE DYNAMICS OF RAL RESISTANCE
EVOLUTION IN VIVO
Further insight into HIV resistance to RAL was ob-
tained when investigators analysed the evolution of vi-
ral genotypes during the course of prolonged RAL
failure. The first findings produced by these studies re-
vealed that viral genotypes tend to change when HIV
continues to evolve under pharmacological pressure by
RAL in vivo [4, 15, 17, 18, 32, 50]. In particular, viruses
carrying mutations of the N155H pathway, whether
N155H alone or N155H associated with one or more
secondary mutations, appear to switch to genotypes ex-
pressing either mutations of the Q148R/H/K or of
the Y143R/C pathways. Remarkably, analysis of indi-
vidual clones from plasma HIV sequences revealed
that the three mutional pathways leading to RAL resis-
tance are in fact mutually exclusive [17, 18, 32]. None
of the viral sequences examined in these studies re-
vealed associations of mutation N155H with muta-
tions Q148R/H/K or Y143R/C on the same clones.
As shown on figure 2, viral sequences present in pa-
tient plasma after several weeks of viral escape under
RAL pressure are a mixed population of viral genomes
carrying mutations characteristic of either of the three
main mutational pathways, with mutations of each
pathway carried by distinct viral genomes. Thus, the
apparent emergence of mutations belonging to the
Q148R/H/K pathway or of the Y143R/C pathways in
the context of preexisting mutations of the N155H
pathway reflects the replacement of viruses carrying
mutations of the N155H pathway by viruses carrying
mutations belonging to either of the two other path-
ways. According to this unique pattern of RAL resis-
tance evolution, it appears that mutations of the
N155H pathway, and particularly mutation N155H it-
self, may be the easiest way for HIV to acquire resis-
tance to RAL early in the course of viral escape, but
that further replication under RAL pressure almost al-
ways leads to dominance of viral genomres carrying
mutations of the two other pathways. In the early
weeks of RAL failure, when N155H genomes consti-
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Fig. 2. (A) clonal analysis of the evolution of HIV RAL resis-
tance over time in two patients (from Malet et al., J Antimi-
crob Chemother 2009). The bars indicate the relative propor-
tion of each mutational pathway within the population of viral
clones sequenced. (B) clonal analysis of the evolution of RAL
resistance over time in one patient (from Fransen et al., An-
timicrob Agents Chemother 2009). The bars indicate the rela-
tive proportion of each mutational pathway within the popula-
tion of viral clones sequenced.
B
A
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tute the dominant resistant species in the viral popula-
tion, viral genomes expressing different substitutions
at position 148 can coexist as minority species that
compete against each other. As illustrated on figure
2A, these genomes can only become dominant once
they have acquired an appropriate secondary mutation
140S. Several observations, however, suggest that
N155H may not be the only mutation to initiate RAL
resistance evolution. Cases of “secondary” mutations
L74M and/or E92Q emerging first have been de-
scribed. In other instances, mutations of the
Q148R/H/K or of the Y143R/C pathways are ob-
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Fig. 3. Phenotypic effect of secondary
mutations on viruses carrying primary
RAL resistance mutations (from Fransen
et al., J Virol 2009). nd : not done.
Fig. 4. Selective advantage curves for
viruses carrying one or two RAL resis-
tance mutations (from Quercia et al., J
Virol 2009). The selective index is calcu-
lated as a ratio of mutant:wild-type infec-
tivity as a function of raltegravir concen-
tration. The blue area indicates values
blelow 1, where mutant viruses do not
express selective advantage relative to
wild-type virus.
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served at a very early stage with no trace of N155H
having been selected beforehand, suggesting that in
these viruses, Q148R/H/K or Y143R/C could consti-
tute a preferable early pathway for initial viral breach
during RAL treatment.
PHENOTYPIC PROPERTIES OF RAL RESISTANCE
MUTATIONS
The dynamics of HIV evolution under pharmacologi-
cal pressure by RAL in vivo are largely explained by the
phenotypic properties of the different IN mutants in-
volved in this evolution, both in terms of resistance
(fold-change in IC50) and in terms of replicative ca-
pacity (RC). Most studies have focused on the effect of
primary and secondary mutations of the N155H and
Q148R/H/K pathways, leaving aside the Y143R/C
pathway, for which little information is available. Phe-
notypic analysis of viral clones carrying the N155H
mutation have found that it mediated significant but
moderate levels of resistance to RAL. Introduction of
N155H in a wild-type HIV-1 subtype B reference mol-
ecular clone such as HIV-1 IIIB or pNL4-3 produced a
change in RAL IC50 of 16- to 32-fold, at the expense
of minimal (30%-40%) loss of replicative capacity.
Mutations at codon 148 appeared to produce stronger
changes in RAL IC50 (18- to 78-fold, depending on
the substitution and on the experimental system), to-
gether with a more prominent loss (40%-70%) of RC.
Thus, N155H produces less resistance than
Q148R/H/K, but had a milder impact on viral RC.
When examined using the “selective advantage profile”
system, which incorporates drug susceptibility and RC
in a single assay expressing the selective advantage of a
mutant virus relative to wild-type as a function of drug
concentration [34, 42, 44], N155H had clearly a strong
positive advantage over a wide range of RAL concen-
tration, as opposed to Q148H [44], which only ex-
pressed minimal selective advantage over wild-type
across a markedly narrower range of RAL concentra-
tion (Fig. 4). Addition of secondary mutations both to
N155H and to Q148R/H/K mutations dramatically
increased RAL resistance and significantly improved
RC [10, 17, 40, 44]. The association of either of the
Q148 mutations with secondary G140S, G140A or
E138K could produce fold-changes in IC50 that were
above the maximal 150-fold resistance rate measurable
in the Monogram assay in Fransen et al. [17], but this
effect was only seen with specific pairs of Q148 and
G140 substitutions. For example, secondary mutation
G140S was found to exert maximal effect only when
associated with Q148H or Q148R, but its association
with Q148K reduced resistance from a 48-fold change
in IC50 to a 6 fold-change, an effect that appears to be
independent of viral RC [17]. Consistent with these
findings, Quercia et al. reported that G140S produced
a change in RAL IC50 of 1436-fold [44]. The addition
of secondary mutation E92Q also markedly increased
the level of resistance conferred by mutation N155H
with E92Q : viruses with both mutations expressed
changes in RAL IC50 of >150-fold in Fransen et al.
and of 492-fold in Quercia et al [17, 44]. When
analysed using the selective advantage profile method,
the combination of Q148H and G140S was found to
express a level of advantage that was higher and wider
than any of the other dual mutations tested. In addi-
tion to their effect on resistance, the association of
G140 mutations with Q148R/H/K mutations also
helps improving viral RC. For example, in Fransen et
al., addition of G140S to Q148H increased RC from
43% of wild type to 99%. Similar findings were report-
ed by Quercia et al. and Delelis et al [10, 44]. Taken to-
gether, these findings reveal that as predicted, N155H
appears to be one of the less costly and most efficient
solutions for RAL resistance when present on the HIV
genome as a single mutation, explaining its frequent
predominance in viral populations harvested early in
the course of viral resistance evolution. While this mu-
tation dominates, however, viral populations carrying
other primary mutations of the Q148R/H/K or of the
Y143R/C pathways are selected but cannot dominate
as long as they only carry single mutations. When these
viruses acquire secondary mutations such as G140A/S
or E138A/K, however, the resulting gain in resistance,
together with the improvement in viral RC allows rapid
expansion and further dominance of these pathways
over the initial N155H mutants. The rapidity of these
population changes may be dependent on the extent
that N155H mutants, alone or in combination with
secondary mutations can suffice to promote pharma-
cologically relevant levels of resistance. Indeed, the
IC50 fold-changes observed in primary viruses ex-
pressing the N155H mutation alone appear to vary sig-
nificantly from one viral strain to another [17], strongly
suggesting that this mutation may exert different levels
of resistance to RAL according of the viral genetic
background. This parameter, together with the concen-
tration of raltegravir found at the site of resistant virus
selection, which may significantly vary from one pa-
tient to another, could also exert a strong effect on the
kinetics of genetic switch from the N155H pathway to
the Q148R/H/K pathway in vivo.
MOLECULAR MECHANISMS OF RAL RESISTANCE
The strand-transfer reaction that leads to HIV DNA
integration into host cellular DNA is catalysed by a dy-
namic complex associating an IN tetramer and the two
ends of the linear viral DNA molecule [1, 13, 14, 19,
25, 30, 38]. Studies conducted using INSTIs have
found that the binding site for this family of drugs is
constituted both by elements of the enzyme itself and
by elements of viral DNA. More specifically, these
studies have pointed to the important role of a mobile
loop structure that is located next to the D64-D116-
E152 catalytic triad and that is critical for the confor-
mation of the IN active site. This loop structure is im-
portant both for binding of the ends of viral DNA to
the IN tetramer and for catalytic activity. Once viral
DNA is bound to the enzyme, the loop, together with
the recessed 3’ end and the 5’ overhang of the
processed viral DNA molecule, will undergo a change
in conformation and participate in the creation of a
hydrophobic pocket able to bind INSTIs. Some of the
most important RAL resistance mutations, such as
Q148R/H/K, Y143R/C and G140A/S, are located
within this active site loop, which extends from
residues 139 to 149. In particular, residues Q148 and
Y143 have been described as directly involved in the
interaction of IN with viral DNA. Residue N155,
which is involved in early RAL resistance in vivo, is lo-
cated within a more structured region of the catalytic
core domain, between the active site and two residues
also known to bind viral DNA at positions 156 and
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159. Overall, current models propose that RAL resis-
tance mutations affect binding of RAL to the IN cat-
alytic domain both through changes that directly modi-
fy points of contact between the drug and the enzyme
and through changes that modify DNA binding to IN.
Similar to current models proposed for HIV resistance
to protease inhibitors, one can predict that secondary
mutations will create subtle structural readjustments
able to compensate for the functional imbalance creat-
ed by structural changes imparted to the IN-DNA
complex by primary mutations, and by the same
process able to reinforce the effect of these mutations
on inhibitor binding and potency.
HIV DIVERSITY AND RAL SUSCEPTIBILITY
In spite of being one of the most conserved HIV pro-
teins, significant variation of the IN aminoacid se-
quence can be seen within and between the different
HIV-1 subtypes [5, 31, 39]. Some of the natural IN
polymorphisms observed between HIV-1 strains have
also been found to emerge in the course of resistance
to RAL, a situation that is reminiscent of what is seen
with protease inhibitors. In particular, polymorphims
V72I, V74M/I, T97A, M154I, V165I and T206S are
found with a frequency greater than 12% in some HIV-
1 subtypes [39]. Key resistance mutations N155H,
Q148R/H/K and Y143R/C, however, are extremely
rare in the absence of pharmacological pressure by
RAL. Consequently, all RAL-naïve viral isolates tested
so far retain near wild-type RAL susceptibility [53].
Similarly, HIV-1 group O and HIV-2 are naturally sus-
ceptible to RAL in vivo [11, 47, 56]. In HIV-2, recent
data have shown that similar to HIV-1, resistance to
RAL following in vivo viral escape is accompanied by
early selection of viral genomes carrying mutation
N155H, which in one instance was later replaced by a
genotype expressing mutation Y143C [47, 56].
CROSS-RESISTANCE
All currently developed INSTIs interact with the cat-
alytic core domain of IN and block HIV DNA integra-
tion into host cell DNA through a similar mechanism
that relies upon comparable diketo-derived key phar-
macophores [35, 48]. Therefore, significant cross resis-
tance is expected between the different INSTIs, an ex-
pectation that has been confirmed by most studies
confronting this question. Following RAL, the most
clinically advanced INSTI molecule is elvitegravir
(EVG, formerly GS-9137), which is now in phase 3 de-
velopment. Unlike RAL, EVG is metabolized by cy-
tochrome P450 and can benenefit of pharmacological
boosting by ritonavir or other P450 antagonists, there-
by allowing for a single daily dosing. Early studies on
EVG resistance [21, 28, 49] have found that this drug
was able to select for mutations E92Q, T66I and
E138K, which have already been found in viruses es-
caping RAL, and for substitutions affecting aminoacids
146 and 147, next to key RAL resistance aminoacid
Q148. Further selection experiments confirmed the
central role of mutation E92Q and the frequent occur-
rence of E138E/K, Q148R, L74M and S230R in EVG
resistance. These findings thus predicted significant
cross-resistance between EVG and RAL. Phenotypic
testing of viruses carrying various combinations of
RAL resistance mutations including T66I, L74M,
E92Q, E138K, G140S, G148R/H/K and N155H con-
firmed extensive cross-resistance between RAL and
EVG, in particular for viruses expressing combinations
of mutations G140S and Q148R/H/K, which repre-
sent the majority of viruses having evolved under pro-
longed selective pressure by RAL [21, 26]. Similar
cross-resistance was also found between RAL and GS-
9160, a novel compound at early stages of develop-
ment by Gilead Sciences [26]. Two INSTIs have been
recently developed jointly by Shionogi and GSK :
S/GSK-364735 and S/GSK-1439572. While extensive
cross-resistance between RAL and S/GSK-364735 has
been described [20], cross-resistance between RAL and
S/GSK-1439572 appears more limited [52]. In vitro se-
lection using this drug leads to emergence of sustitu-
tion T124A, a common IN polymorphism that does
not affect INSTI susceptibility, and of mutation S153F,
at a position already found to mutate under pressure by
diketo acid derivatives. In vitro susceptibility of com-
mon RAL resitant mutants to S/GSK-1439572 reveals
that only combination of mutations G140S and
Q148R/H reaches fold-changes in S/GSK-1439572
susceptibility above 10-fold, as compared with several
hundred-fold for RAL. In spite of these encouraging
results, further testing of primary viruses having accu-
mulated multiple primary and secondary mutations and
reached high-level resistance under RAL pressure is re-
quired before ensuring S/GSK-1439572 as a second-
line INSTI drug with significant antiviral activity in pa-
tients having failed RAL-based treatment.
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